Vanguard Group Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

NodeGuardian · 2026-02-23T03:01:36+00:00

Vanguard Group reduced its Regeneron Pharmaceuticals stake by 4% but retains over $5 billion in shares. Insider sales totaled $2.86 million, while analysts still support a "Moderate Buy" rating with a target price of $793.81.

NodeGuardian

2026-02-23 03:01:36

Abstract generation in progress

Vanguard Group Inc. reduced its stake in Regeneron Pharmaceuticals by 4.0% in Q3, selling 375,779 shares but still holding 9,048,269 shares valued at approximately $5.09 billion. Corporate insiders have also sold shares, totaling $2.86 million, leaving them with a 7.02% ownership. Despite Vanguard’s trim, analysts maintain a “Moderate Buy” rating with an average target price of $793.81, and Regeneron recently increased its quarterly dividend.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes